Navigation Links
Raymond J. Ruddy Joins Psychemedics Corporation As Top Financial Officer

ACTON, Mass., Oct. 20 /PRNewswire-FirstCall/ -- Psychemedics Corporation (Nasdaq: PMD) today announced that Raymond J. Ruddy has joined the company as Vice President, Controller.

Ray will be responsible for all internal and external financial reporting activities, as well as the financial analysis and planning activities necessary for the company's continued growth. Ray will report directly to the Chairman and CEO.

Since 2005, Ray has served as Director of International Finance of GSI Group Corporation. From 2001 to 2005 Ray served as Director of Finance and Investor Relations of Concord Communications. He began his career in the audit department at Ernest & Young LLP and proceeded to work in positions of increasing responsibilities with three additional firms before joining Concord Communications. Ray is a CPA who received his BA from The College of the Holy Cross and his MBA from the Yale University School of Management.

Raymond C. Kubacki, Chairman and CEO stated, "We are extremely pleased to have Ray join our team. He comes to us with a strong proven track record that fits extremely well with the needs of our company. His strong analytical skills and broad experience base will be very important in determining and controlling costs and expenses, as well as analyzing other key metrics in our business needed to accelerate our growth. Ray will be our top financial officer and we are extremely pleased to have him on board."

Psychemedics is the world's largest provider of testing for drugs of abuse using hair analysis with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and Federal Reserve Banks.

The Psychemedics web site is

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning growth, earnings, profit margins, earnings per share, revenues, dividends, future business, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward-looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing network, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.

Contact: Raymond C. Kubacki

Chairman, President and CEO

(978) 206-8220

SOURCE Psychemedics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement by American Heart Association Immediate-Past President Raymond Gibbons, M.D. on Congressional Omnibus Spending Bill
2. SXC Health Solutions to present at Raymond James 29th Annual Institutional Investors Conference
3. Gentiva(R) Health Services to Present March 3rd at Raymond James 29th Annual Institutional Investors Conference in Orlando
4. MedCath Corporation to Present at the Raymond James 29th Annual Institutional Investors Conference
5. Hologic to Present at the Raymond James & Associates 29th Annual Institutional Investors Conference
6. Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference
7. Covance to Present at Raymond James 29th Annual Institutional Investors Conference
8. Emageon to Present at Raymond James 29th Annual Institutional Investors Conference
9. Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors
10. Richard Greco Joins Mediware Board
11. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
Post Your Comments:
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they ... to buy during the Black Friday and Cyber Monday massage chair sales ... the Internet high and low to find the best massage chair deals, they can ...
(Date:11/26/2015)... ... 26, 2015 , ... The Catalent Applied Drug Delivery Institute ... integrate dose form selection in early phase drug development. The first of these ... bringing together the UK’s emerging life sciences companies, corporate partners, and investors, at ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... second medical opinion process, participated in the 61st annual Employee Benefits Conference. The ... and took place Sunday, November 8th through Wednesday, November 11th, 2015. The conference ...
(Date:11/26/2015)... ... 26, 2015 , ... Indosoft Inc., developer and distributor of the world-class Asterisk ... system efficiency and reliability. , The new Q-Suite 6 platform is based on the ... locking itself into a specific piece of software for many key components of the ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
Breaking Medicine Technology: